Login to Your Account



Inflectra reflects guidance on biosimilar names, labeling

By Mari Serebrov
Regulatory Editor

Tuesday, April 5, 2016

Stepping out Tuesday as the second biosimilar approved in the U.S., Pfizer Inc.'s Inflectra is decked out in a label, replete with extrapolated indications, that reflects the FDA's most recent guidance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription